Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Core Viewpoint - Biodexa Pharmaceuticals PLC has announced the recruitment of the first patient in a Phase 2 study of tolimidone for Type 1 Diabetes, indicating progress in its clinical development pipeline [2][3]. Group 1: Study Details - The Phase 2 study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute, focusing on measuring C-peptide levels and HbA1c after three months in 12 patients across three dose groups [3]. - The study aims to assess the number of hyperglycemic events and may expand in the future [3]. Group 2: Drug Background - Tolimidone was originally discovered by Pfizer and developed through Phase II for gastric ulcers but was discontinued due to lack of efficacy [5]. - It is a selective activator of Lyn kinase, which enhances insulin signaling by increasing phosphorylation of insulin substrate-1 [5][8]. - Preclinical studies at the University of Alberta have shown tolimidone's potential to induce beta cell proliferation, which is crucial for insulin production [4]. Group 3: Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs, including tolimidone for Type 1 Diabetes [6]. - The company's other lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, and MTX110 for aggressive rare/orphan brain cancer [6].